Anaplastic Lymphoma Kinase (ALK), D5F3, CDx, IHC
Also known as: VENTANA® ALK (D5F3) CDx Assay
Use
This immunohistochemical assay detects the presence of anaplastic lymphoma kinase (ALK) protein in formalin-fixed paraffin‑embedded non‑small‑cell lung carcinoma (NSCLC) specimens, serving as an aid in identifying NSCLC patients eligible for ALK‑targeted therapies such as crizotinib, ceritinib, lorlatinib, or alectinib.
Special Instructions
Pertinent clinical diagnosis, including pathology report documenting pulmonary origin, should be included with the specimen.
Limitations
Not provided.
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
2-5 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
One formalin‑fixed, paraffin‑embedded (FFPE) tissue block or five unstained positively charged slides sectioned from FFPE tissue block at 4 to 5 microns
Minimum Volume
Three unstained tissue slides
Collection Instructions
Tissue should be fixed in 10% neutral buffered formalin a minimum of six hours and no more than 72 hours. Embed in paraffin.
Storage Instructions
Room temperature
Causes for Rejection
Insufficient tissue; inappropriate tissue source; incorrect specimen type; decalcified specimens
Other tests from different labs that may be relevant